In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery platform, which uses high-resolution crystallography to target viral regions resistant to mutation, enabling broad‑spectrum antivirals. The discussion highlights Cocrystal’s lead candidate, CDI‑988, a dual‑indication antiviral for coronaviruses and noroviruses, with a particular focus on advancing the norovirus program due to high global unmet need. Martin outlines the ongoing human challenge norovirus study at Emory University, CDI‑988’s potential as therapy and prophylactic, and growing U.S. government and military interest. The episode also highlights the company' upcoming milestones, including mid‑2026 top-line data for the CDI-988 human challenge study, and an overview of its broader pipeline, including influenza A and B programs.

Best,

In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, beginning with binge eating disorder. The discussion also covers Entropy’s work on real‑time EEG and brain entropy as a potential biomarker, the company’s financing, regulatory roadmap, and longer‑term expansion opportunities in areas such as PTSD.

In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa’s two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how Anixa differentiates itself through both its scientific platforms and disciplined financial management.